to plasma mGFR.TDI was 55.7, signifying 90% of the DBS mGFR showed an error ranging from -55.7% to + 55.7% of the plasma mGFR. Conclusion:DBS is a promising low-volume method for estimating mGFR but currently demonstrate only moderate agreement with plasma mGFR.The data highlight the needs for standardisation for DBS sampling and analysis before it can be reliably applied in clinical aspects.I have no potential conflict of interest to disclose.I did not use generative AI and AI-assisted technologies in the writing process.
Lalwani et al. (Wed,) studied this question.